While this has yet to result in a new therapy for ARID1A-mutated tumours, the identification of a drug(s) that targets and abolishes ARID1B function in ARID1A-mutated tumours could represent a new therapeutic strategy for OCCC. This evidence concerns the gene ARID1B and neoplasm.